Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase

Pediatric Blood and Cancer

Volumn 61, Issue 2, 2014, Pages 355-357

  Millot, Frédéric ^a   Claviez, Alexander ^b   Leverger, Guy ^c   Corbaciglu, Selim ^d   Groll, Andreas H ^e   Suttorp, Meinolf ^f  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Children; Chronic myeloid leukemia; Complete molecular response; Imatinib

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGISTRY; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT RESPONSE;

EID: 84890882443     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24521     Document Type: Article

References (10)

1. Millot F, Baruchel A, Guilhot J, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial. J Clin Oncol 2011; 29:2827-2832.
2. Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11:1029-1035.
3. Bansal D, Shava U, Varma N, et al. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer 2012; 59:481-484.
4. Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 2011; 159:676-681.
5. Jaeger BAS, Tauer JT, Ulmer A, et al. Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment. Med Sci Monit 2012; 18:CR721-CR728.
6. Ross DM, Bartley PA, Goyne J, et al. Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features. Haematologica 2011; 96:1720-1722.
7. Takahashi N, Kyo T, Maeda Y, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 2012; 97:903-906.
8. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104:2204-2205.
9. Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004; 28:S71-S73.
10. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic response on imatinib. J Clin Oncol 2010; 20:2381-2388.